« Zurück
Startseite /
Canertinib (dihydrochloride)

Canertinib (dihydrochloride)

ArtNr	HY-10367A-10mM
Hersteller	MedChem Express
CAS-Nr.	289499-45-2
Menge	10 mM/1 mL
Quantity options	100 mg 10 mM/1 mL 10 mg 200 mg 500 mg 50 mg 5 mg
Kategorie	Oncology Neuroscience Neural Lineage Markers Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Bladder Cancer Breast Cancer Neuronal Cell Markers
Typ	Inhibitors
Specific against	other
Purity	99.68
Citations	[1]Smaill JB, et al. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. J Med Chem. 2000 Apr 6;43(7):1380-97.\|[2]Djerf Severinsson EA, et al. The pan-ErbB receptor tyrosine kinase inhibitor canertinib promotes apoptosis of malignant melanoma in vitro and displays anti-tumor activity in vivo. Biochem Biophys Res Commun. 2011 Oct 28;414(3):563-8.\|[3]McAndrews KM, et, al. Mechanisms associated with biogenesis of exosomes in cancer. Mol Cancer. 2019 Mar 30;18(1):52.\|[4]Smee DF, et, al. Progress in the discovery of compounds inhibiting orthopoxviruses in animal models. Antivir Chem Chemother. 2008;19(3):115-24. Harvard Medical School LINCS LIBRARY\|J Cell Sci. 2015 Sep 1;128(17):3317-29. \|Biochemistry. 2017 Jun 13;56(23):2921-2927.\|Biochemistry. 2018 Feb 27;57(8):1369-1379.\|bioRxiv. 2023 Oct 6.\|J Biol Chem. 2012 Mar 23;287(13):9742-52.\|J Med Chem. 2019 May 9;62(9):4772-4778.\|Oncotarget. 2020 Nov 3;11(44):3921-3932.\|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.
Smiles	C=CC(NC1=CC2=C(N=CN=C2C=C1OCCCN3CCOCC3)NC4=CC=C(C(Cl)=C4)F)=O.[H]Cl.[H]Cl
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	CI-1033 dihydrochloride,PD-183805 dihydrochloride
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	EGFR; Orthopoxvirus
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	558.86
Product Description	Canertinib dihydrochloride (CI-1033 dihydrochloride) is a potent and irreversible EGFR inhibitor; inhibits cellular EGFR and ErbB2 autophosphorylation with IC50s of 7.4 and 9 nM. Canertinib dihydrochloride is active against vaccinia virus respiratory infection in mice[1][2][3][4].
Manufacturer - Research Area	Cancer; Infection
Solubility	DMSO : 62.5 mg/mL (ultrasonic)\|H2O : 25 mg/mL (ultrasonic)
Manufacturer - Pathway	Anti-infection; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Clinical information	Phase 2
Isoform	EGFR/ErbB1/HER1; ErbB2/HER2

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-10367A-10mM-safety-datasheet.pdf